180 Life Sciences Corp. Files 8-K Report
Ticker: FRMM · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1690080
| Field | Detail |
|---|---|
| Company | 180 Life Sciences CORP. (FRMM) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $3,806, $349 million, $238 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, 8-K, financial-statements
TL;DR
180 Life Sciences filed an 8-K on Aug 12, 2025, covering Reg FD and other events.
AI Summary
On August 12, 2025, 180 Life Sciences Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial statements and exhibits. The company, formerly known as KBL Merger Corp. IV until November 15, 2016, is incorporated in Delaware and is involved in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing provides an update on corporate events and financial information for 180 Life Sciences Corp., which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former Company Name
- August 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- November 15, 2016 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures, other events, and to include financial statements and exhibits.
When was the report filed?
The report was filed on August 12, 2025.
What was the company's former name?
The company's former name was KBL Merger Corp. IV.
When did the company change its name?
The company changed its name on November 15, 2016.
In which state is 180 Life Sciences Corp. incorporated?
180 Life Sciences Corp. is incorporated in Delaware.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-08-12 08:01:15
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
- $3,806 — ETH at an average acquisition price of $3,806.71, which is now valued at approximatel
- $349 million — 1, which is now valued at approximately $349 million. In addition to the ETH, the Company ho
- $238 million — he ETH, the Company holds approximately $238 million in USD cash equivalents. The purchases
Filing Documents
- ea0252766-8k_180life.htm (8-K) — 31KB
- ea025276601ex99-1_180life.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-074637.txt ( ) — 265KB
- atnf-20250812.xsd (EX-101.SCH) — 4KB
- atnf-20250812_def.xml (EX-101.DEF) — 26KB
- atnf-20250812_lab.xml (EX-101.LAB) — 36KB
- atnf-20250812_pre.xml (EX-101.PRE) — 25KB
- ea0252766-8k_180life_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 12, 2025, 180 Life Sciences Corp. (the " Company ") issued a press release announcing that the Company has initiated its ETH accumulation strategy and disclosing the Company's ETH holdings to date. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1 is being furnished to the U.S. Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. ETH Accumulation Status Update As of August 11, 2025, the Company has acquired 82,186 ETH at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, the Company holds approximately $238 million in USD cash equivalents. The purchases were made using certain of the net proceeds the Company received from the Company's previously disclosed private PIPE offering and sale of convertible notes.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2025 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Chief Executive Officer 2